Chiusura precedente | 28,80 |
Aperto | 28,21 |
Denaro | 27,56 x 100 |
Lettera | 27,70 x 100 |
Min-Max giorno | 27,44 - 28,29 |
Intervallo di 52 settimane | 15,90 - 45,58 |
Volume | |
Media Volume | 1.154.156 |
Capitalizzazione | 4,025B |
Beta (5 anni mensile) | 0,70 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,81 |
Prossima data utili | 13 mag 2024 - 27 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 50,86 |
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the closing of its previously announced underwritten public offering of 8,475,500 shares of its common stock at a price of $38.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,105,500 additional shares of common stock. Concurrent with the publ
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions. All of
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the commencement of a proposed underwritten public offering and concurrent private placement of an aggregate of $300,000,000 of shares of its common stock. Immunovant intends to offer and sell $130,000,000 of shares of its common stock in an underwritten public offering. In addition, Immunovant in